[Clinical and biochemical considerations on depressive states occuring during parkinsonian syndrome treated by L-Dopa].
From 17 observations of depressive illness occuring to parkinsonians treated with L. Dopa alone or associated with an inhibitor of peripheral decarboxylase, several types of depressive illness can be distinguished according to their date of appearance, their evolution with or without tricyclic anti-depressant drugs tertiary amine. According to the characteristics of these depressive illness, to the related locomotive state and to various monoamingeric hypothesises that are suggested both in the genesis of affective disorders and the mechanism of action of two biochemically related depressive aspects, a distinction already considered by other authors for endogeneous depressions.
D000368:Aged; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002395:Catecholamines / Q000378:metabolism; D003863:Depression / Q000139:chemically induced* / Q000378:metabolism; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002395:Catecholamines; D007980:Levodopa
Considérations cliniques et biochimiques sur les états dépressifs survenant lors de syndromes parkinsoniens traités par la L Dopa